NCT06277492View on ClinicalTrials.gov

A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

February 19, 2024

Primary Completion Date

July 11, 2025

Study Completion Date

November 8, 2025

Conditions
Healthy Subjects
Interventions
DRUG

Single ascending doses SUL-238

PART 1: SUL-238 single ascending doses

DRUG

Single dose Placebo

PART 1: Placebo single dose

DRUG

Single dose SUL-238

PART 2: SUL-238 single dose for pharmacokinetics

DRUG

Multiple ascending doses SUL-238

PART 3: SUL-238 multiple ascending doses

DRUG

Multiple doses Placebo

PART 3: Placebo multiple doses

DRUG

2000 mg SUL-238 single dose for pharmacokinetics (food effect)

PART 2B: 2000 mg single dose of SUL-238

DRUG

Single dose placebo (food effect)

PART 2B: Placebo single dose

Trial Locations (1)

38030

Erciyes University IKUM Center, Kayseri

All Listed Sponsors
collaborator

Sulfateq B.V.

UNKNOWN

lead

GEN İlaç ve Sağlık Ürünleri A.Ş.

INDUSTRY